The researchers performed literature studies in six medical databases and identified 45 cost-of-illness studies published between 1988 and June 2014. Most (84 percent) of the studies were from the U.S., although the researchers also used studies from Australia, Canada, Germany, Ireland, Japan and the U.K.
Analyzing these studies, the researchers found an attributable mean C. diff cost that ranged from $8,911 to $30,049 per hospitalized patient.
“Decision-makers can use cost-of-illness studies to aid in strategic planning, and researchers can incorporate [cost-of-illness] estimates in economic evaluations that, in turn, inform health policy,” wrote the study authors.
More articles on C. diff:
Leukemia patients at high risk for C. diff infections, study finds
Long Island hospital receives Pinnacle award for reducing C. diff
Giving nonaggressive C. diff to recovered patients reduces risk of C. diff recurrence, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
